期刊文献+

肿瘤化疗所致血小板减少症患者处方合理性分析 被引量:2

The prescription rationality analysis of thrombocytopenia caused by chemotherapy
下载PDF
导出
摘要 目的针对肿瘤化疗致血小板减少症患者进行专项处方点评,促进临床合理用药。方法对408例肿瘤化疗致血小板减少症患者处方用药进行点评与分析。结果临床使用升血小板药物时,不合理用药率为86.03%(351/408),常见的用药不适宜包括超适应证用药,用药疗程不适宜,药物剂量不适宜等。结论开展专项处方点评有利于促进临床合理用药。 Objective Special prescription reviews on patients with thrombocytopenia caused by chemotherapy,promote clinical rational drug. Methods Conduct reviews and analysis on the prescription of 408 cases patients with thrombocytopenia caused by cancer chemotherapy. Results Clinical use L-platelet drugs,irrational drug use was 86. 03%( 351 /408),common inappropriate medication were off-label drug use,inappropriate drug treatment,dose inappropriate. Conclusion Carry out special prescription reviews is beneficial to promote clinical rational drug.
作者 赵敏 吴楠
出处 《临床合理用药杂志》 2016年第22期31-32,共2页 Chinese Journal of Clinical Rational Drug Use
基金 江苏省药学会-奥赛康医院药学基金项目(No:201314)
关键词 肿瘤化疗致血小板减少症 白介素-11 促血小板生成素 处方点评 Chemotherapy-induced thrombocytopenia Interleukin-11 Thrombopoietin Prescription reviews
  • 相关文献

参考文献2

二级参考文献13

  • 1[1]Farese AM, Hunt P, Boone T, et al. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal non-human primates[ J]. Blood, 1995,86:54 ~59.
  • 2[2]Sprugel KU,Humes TM,Grossman,et al. Recombinant thrombopoietin stimulates rapid platelet recovery in thrombocytopenia mice [ J ].Blood, 1994,84:242a( Supple Ⅰ ).
  • 3[3]Basser RL, Rasko JEJ,Clarke K,et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rhMGFD) in patients with advanced cancer[ J]. Lancet. 1996,348:1279 ~ 1281.
  • 4[4]Basser RL,Rasko JEJ,Clarke K,et al. Randomized,blinded,placebo -controlled phase Ⅰ trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rhMGFD) with filgrastim after dose-intensive chemotherapy in patients with advanced cancer[ J ]. Blood. 1997,89:3118 ~ 3128.
  • 5[5]Vadhan-Rai S,Verschraegen CF,Bueso-Ramos C,et al. Recombinant human thrombopoietin attenuates carboplastin-induced severe theombocytopenia and the need for platelet transfusions in patients with gynecologic cancer[ J ]. Ann Intern Med. 2000,132:364 ~ 368.
  • 6[6]Vadhan-Rai S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by single dose of recombinant human thrombopoietin in patients with cancer[ J ]. Ann Intern Med,1997,126:673 ~ 681.
  • 7[9]Herzyk DJ. The immunogencity of theraprutic cytokines [ J ]. Curr Opin Mol Ther,2003,5(2) :167 ~ 171.
  • 8[10]Li JZ, Yang C, Xia YP, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin [ J ]. Blood,2001,98: 3241 ~3248.
  • 9[11]Basser RL, O Flaherty E,Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported megakaryocyte growth and development factpr[ J]. Blood,2002,99:2599 ~ 2602.
  • 10[12]Kuter DJ,Begley CG. Recombinant human thrombopoietin:basic biology and evaluation of clinical studies[ J]. Blood,2002,100:3457~ 3469.

共引文献16

同被引文献11

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部